Crossmark

Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials

Crossref DOI link: https://doi.org/10.14283/jpad.2022.25

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cummings, J.
License Information

Text and Data Mining valid from 2022-04-01

Text and Data Mining valid from 2022-04-01

Version of Record valid from 2022-02-04
More Information

This article is maintained by: Elsevier

Article Title: Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2022.25

Content Type: article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below